Retinopathy. Clinical Trial
NCT number | NCT01229540 |
Other study ID # | 08ZCGYSF01700 |
Secondary ID | 08ZCGYSF01700 |
Status | Terminated |
Phase | N/A |
First received | October 26, 2010 |
Last updated | October 26, 2010 |
Verified date | September 2008 |
Source | Tianjin Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Ethics Committee |
Study type | Interventional |
Retinal neovascularization of diabetic retinopathy might be associated with genetic risk factors and environmental risk factors.
Status | Terminated |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 45 Years to 74 Years |
Eligibility |
Inclusion Criteria: - T2DM was diagnosed according to the World Health Organization Expert Consultation Report 1999 and consisted of one of the following: fasting blood glucose (FBG) =7.0 mmol/L (=126 mg/dL), blood glucose =11.1 mmol/L (=200 mg/dL) 2 hours after an oral glucose tolerance test (OGTT); or a random blood glucose =11.1 mmol/L (=200 mg/dL). - DR was clinically graded in accordance with the International Clinical Diabetic Retinopathy guidelines based on fundus fluorescence angiography. - All participants with PDR underwent a comprehensive dilated fundus examination to detect DR by indirect ophthalmoscopy and were diagnosed by fundus fluorescence angiography. Exclusion Criteria: - Patients were excluded if they had acute complications of diabetes mellitus, type 1 diabetes mellitus, other types of diabetes, serious cardiovascular, hepatic, nephritic or other complications, other serious primary diseases or mental illness. |
N/A
Country | Name | City | State |
---|---|---|---|
China | Tianjin Eye Hospital, Clinical college of Ophthalmology ,Tianjin Medical Univercity | Tianjin | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Tianjin Medical University |
China,